The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dyskinesias


Psychiatry related information on Dyskinesias


High impact information on Dyskinesias


Chemical compound and disease context of Dyskinesias


Biological context of Dyskinesias


Anatomical context of Dyskinesias


Gene context of Dyskinesias


Analytical, diagnostic and therapeutic context of Dyskinesias


  1. Posteroventral medial pallidotomy in advanced Parkinson's disease. Lang, A.E., Lozano, A.M., Montgomery, E., Duff, J., Tasker, R., Hutchinson, W. N. Engl. J. Med. (1997) [Pubmed]
  2. Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy. Grimes, J.D. N. Engl. J. Med. (1981) [Pubmed]
  3. Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Gusella, J.F., Tanzi, R.E., Bader, P.I., Phelan, M.C., Stevenson, R., Hayden, M.R., Hofman, K.J., Faryniarz, A.G., Gibbons, K. Nature (1985) [Pubmed]
  4. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Karpuj, M.V., Becher, M.W., Springer, J.E., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D., Steinman, L. Nat. Med. (2002) [Pubmed]
  5. Treatment of Parkinson's disease with lergotrile mesylate. Lieberman, A., Estey, E., Kupersmith, M., Gopinathan, G., Goldstein, M. JAMA (1977) [Pubmed]
  6. Identification of an Alu retrotransposition event in close proximity to a strong candidate gene for Huntington's disease. Goldberg, Y.P., Rommens, J.M., Andrew, S.E., Hutchinson, G.B., Lin, B., Theilmann, J., Graham, R., Glaves, M.L., Starr, E., McDonald, H. Nature (1993) [Pubmed]
  7. Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Klein, R., Silos-Santiago, I., Smeyne, R.J., Lira, S.A., Brambilla, R., Bryant, S., Zhang, L., Snider, W.D., Barbacid, M. Nature (1994) [Pubmed]
  8. Tardive dyskinesia following haloperidol treatment in Tourette's syndrome. Riddle, M.A., Hardin, M.T., Towbin, K.E., Leckman, J.F., Cohen, D.J. Arch. Gen. Psychiatry (1987) [Pubmed]
  9. Paroxysmal dystonic choreoathetosis: tight linkage to chromosome 2q. Fink, J.K., Rainer, S., Wilkowski, J., Jones, S.M., Kume, A., Hedera, P., Albin, R., Mathay, J., Girbach, L., Varvil, T., Otterud, B., Leppert, M. Am. J. Hum. Genet. (1996) [Pubmed]
  10. Propranolol-induced tardive dyskinesia in a patient with akathisia. Sandyk, R. Ann. Neurol. (1985) [Pubmed]
  11. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., Eidelberg, D., Fahn, S. N. Engl. J. Med. (2001) [Pubmed]
  12. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., Lang, A.E. N. Engl. J. Med. (2000) [Pubmed]
  13. More on metoclopramide and tardive dyskinesia. Mahler, J.C., Brown, R.P. N. Engl. J. Med. (1987) [Pubmed]
  14. Prolactin levels in tardive dyskinesia. Cohen, K.L., Cooper, R.A., Altshul, S. N. Engl. J. Med. (1979) [Pubmed]
  15. Facilitation of levodopa-induced dyskinesias by dietary carbohydrates. Wurtman, R., Caballero, B., Salzman, E. N. Engl. J. Med. (1988) [Pubmed]
  16. Treatment and prognosis of hemiballismus. Klawans, H.L., Moses, H., Nausieda, P.A., Bergen, D., Weiner, W.J. N. Engl. J. Med. (1976) [Pubmed]
  17. Aggravation of tardive dyskinesia by phenytoin. DeVeaugh-Geiss, J. N. Engl. J. Med. (1978) [Pubmed]
  18. Choline for tardive dyskinesia. Weiss, K.J. N. Engl. J. Med. (1977) [Pubmed]
  19. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Westin, J.E., Vercammen, L., Strome, E.M., Konradi, C., Cenci, M.A. Biol. Psychiatry (2007) [Pubmed]
  20. Improvement in tardive dyskinesia after muscimol therapy. Tamminga, C.A., Crayton, J.W., Chase, T.N. Arch. Gen. Psychiatry (1979) [Pubmed]
  21. Clinical pharmacology of levodopa-induced dyskinesia. Nutt, J.G. Ann. Neurol. (2000) [Pubmed]
  22. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Segman, R., Neeman, T., Heresco-Levy, U., Finkel, B., Karagichev, L., Schlafman, M., Dorevitch, A., Yakir, A., Lerner, A., Shelevoy, A., Lerer, B. Mol. Psychiatry (1999) [Pubmed]
  23. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Basile, V.S., Ozdemir, V., Masellis, M., Meltzer, H.Y., Lieberman, J.A., Potkin, S.G., Macciardi, F.M., Petronis, A., Kennedy, J.L. Mol. Psychiatry (2001) [Pubmed]
  24. Tardive dyskinesia and substrates of energy metabolism in CSF. Goff, D.C., Tsai, G., Beal, M.F., Coyle, J.T. The American journal of psychiatry. (1995) [Pubmed]
  25. Lecithin consumption raises serum-free-choline levels. Wurtman, R.J., Hirsch, M.J., Growdon, J.H. Lancet (1977) [Pubmed]
  26. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Vitek, J.L., Chockkan, V., Zhang, J.Y., Kaneoke, Y., Evatt, M., DeLong, M.R., Triche, S., Mewes, K., Hashimoto, T., Bakay, R.A. Ann. Neurol. (1999) [Pubmed]
  27. Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the subthalamic nucleus. Wenzelburger, R., Zhang, B.R., Poepping, M., Schrader, B., Müller, D., Kopper, F., Fietzek, U., Mehdorn, H.M., Deuschl, G., Krack, P. Ann. Neurol. (2002) [Pubmed]
  28. Neuroimaging of dyskinesia. Brooks, D.J., Piccini, P., Turjanski, N., Samuel, M. Ann. Neurol. (2000) [Pubmed]
  29. Role of neurotrophins in mouse neuronal development. Klein, R. FASEB J. (1994) [Pubmed]
  30. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Kaiser, R., Tremblay, P.B., Klufmöller, F., Roots, I., Brockmöller, J. Mol. Psychiatry (2002) [Pubmed]
  31. Syntaxin 4 expression affects glucose transporter 8 translocation and embryo survival. Wyman, A.H., Chi, M., Riley, J., Carayannopoulos, M.O., Yang, C., Coker, K.J., Pessin, J.E., Moley, K.H. Mol. Endocrinol. (2003) [Pubmed]
  32. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. Arthur, H., Dahl, M.L., Siwers, B., Sjöqvist, F. Journal of clinical psychopharmacology. (1995) [Pubmed]
  33. Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia: confirmation in 2 kindreds. Chen, D.H., Matsushita, M., Rainier, S., Meaney, B., Tisch, L., Feleke, A., Wolff, J., Lipe, H., Fink, J., Bird, T.D., Raskind, W.H. Arch. Neurol. (2005) [Pubmed]
  34. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Calon, F., Hadj Tahar, A., Blanchet, P.J., Morissette, M., Grondin, R., Goulet, M., Doucet, J.P., Robertson, G.S., Nestler, E., Di Paolo, T., Bédard, P.J. Trends Neurosci. (2000) [Pubmed]
  35. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Conn, H.O., Leevy, C.M., Vlahcevic, Z.R., Rodgers, J.B., Maddrey, W.C., Seeff, L., Levy, L.L. Gastroenterology (1977) [Pubmed]
  36. Dopamine agonist monotherapy in Parkinson's disease. Clarke, C.E., Guttman, M. Lancet (2002) [Pubmed]
  37. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Shamir, E., Barak, Y., Shalman, I., Laudon, M., Zisapel, N., Tarrasch, R., Elizur, A., Weizman, R. Arch. Gen. Psychiatry (2001) [Pubmed]
  38. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Bejjani, B.P., Arnulf, I., Demeret, S., Damier, P., Bonnet, A.M., Houeto, J.L., Agid, Y. Ann. Neurol. (2000) [Pubmed]
WikiGenes - Universities